Ventana Launches First IHC BRAF Mutation Test

Ventana Medical Systems, a Roche subsidiary, this week launched an immunohistochemistry test for gauging the BRAF V600E mutation in different tumor types.

The company claims this is the first such commercially available test on the market. Roche also markets a real-time PCR based companion diagnostic on the Cobas platform for assessing BRAF mutations in melanoma patients considering treatment with its BRAF inhibitor Zelboraf (vemurafenib).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.